Malaysia's Pharmaniaga signs COVID vaccine agreement with China's Sinovac
Malaysia Pharmaniaga Bhd has signed an agreement with China's Sinovac to purchase ready-to-fill COVID-19 vaccines and later to manufacture the vaccine domestically, it said on Tuesday.
Reuters | Kuala Lumpur | Updated: 12-01-2021 12:03 IST | Created: 12-01-2021 12:03 IST
Malaysia Pharmaniaga Bhd has signed an agreement with China's Sinovac to purchase ready-to-fill COVID-19 vaccines and later to manufacture the vaccine domestically, it said on Tuesday. Pharmaniaga said in a filing to the bourse that the company will carry out a fill-and-finish process of the vaccine in Malaysia, and will subsequently enter into local manufacturing, under license from Sinovac for its technology and know-how.
"This will also help Pharmaniaga in long-term partnerships, including technology transfer to grow the sector in Malaysia," the company said. Malaysia has been in talks to secure a total of 23.9 million doses of COVID-19 vaccines from Sinovac and another Chinese manufacturer CanSino Biologics, and from Russia's Gamaleya Institute, the maker of the Sputnik V vaccine.
The Southeast Asian nation has also procured coronavirus vaccines from U.S. and German drugmakers Pfizer and BioNTech, as well as British-Swedish biopharmaceutical firm AstraZeneca PLC.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
U.S. orders extra inspection of some Boeing 777s after United incident, Japan suspends use
Chinese diplomat blames former Trump administration for U.S.-China difficulties
U.S. orders extra inspection of some Boeing 777s after United incident, Japan suspends use
Chinese ambassador to U.S. says the two countries must define policy boundaries
U.S. nears 500,000 COVID-19 deaths as Biden plans commemoration